Cargando…

Production, immunogenicity, stability, and safety of a vaccine against Clostridium perfringens beta toxins

BACKGROUND AND AIM: The beta toxin is causing the most severe Clostridium perfringens-related diseases. This work was dedicated to developing a vaccine against beta toxin using C. perfringens type C (NCTC 3180). MATERIALS AND METHODS: The crude toxoid harvest contained 710 limits of flocculation (Lf...

Descripción completa

Detalles Bibliográficos
Autores principales: Saadh, Mohamed J., Sa’adeh, Issam J., Dababneh, Moeen F., Almaaytah, Ammar M., Bayan, Mohammad F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Veterinary World 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7522943/
https://www.ncbi.nlm.nih.gov/pubmed/33061221
http://dx.doi.org/10.14202/vetworld.2020.1517-1523
_version_ 1783588291193339904
author Saadh, Mohamed J.
Sa’adeh, Issam J.
Dababneh, Moeen F.
Almaaytah, Ammar M.
Bayan, Mohammad F.
author_facet Saadh, Mohamed J.
Sa’adeh, Issam J.
Dababneh, Moeen F.
Almaaytah, Ammar M.
Bayan, Mohammad F.
author_sort Saadh, Mohamed J.
collection PubMed
description BACKGROUND AND AIM: The beta toxin is causing the most severe Clostridium perfringens-related diseases. This work was dedicated to developing a vaccine against beta toxin using C. perfringens type C (NCTC 3180). MATERIALS AND METHODS: The crude toxoid harvest contained 710 limits of flocculation (Lf)/mL. The vaccine was formulated. Each 1 mL of the final vaccine product contained at least 50 Lf/mL of beta toxoids, 0.2 mL 3% aluminum hydroxide gel (equivalent to 5.18 mg of aluminum), <0.001% W/V thiomersal, formaldehyde <0.05% W/V, and ~0.7 mL phosphate-buffered saline (pH 7.2). The efficacy of the vaccine was evaluated by potency, stability, and safety tests. RESULTS: The vaccine demonstrated 24.36 IU/mL (standard deviation, ±0.56) and 14.74 IU/mL (±0.36) of neutralizing antibodies in rabbits and cattle, respectively. Indeed, these levels were above the minimum recommended by international protocols since the obtained antibody levels had 2.43- and 1.47-fold increase in both rabbits and cattle, respectively, over the minimum antitoxin level suggested by the United States Department of Agriculture. Interestingly, our formulation was capable of inducing 1.65-fold higher immune responses in rabbits than that stimulated in cattle (65% increase) with a significant difference (p<0.0001). The vaccine was stable up to 30 months. The vaccinated rabbits were suffered from a temporarily slight increase in temperatures in the first 10 h without any significant difference (p>0.05). CONCLUSION: The research showed a procedure for the manufacturing process of the vaccine against C. perfringens beta toxins with a feasible quantity and the vaccine described here showed to be effective in eliciting levels of neutralizing antibodies higher than required by international standards. In addition, The vaccine was stable up to 30 months. Thus, it may represent an effective and safe for preventing C. perfringens-related diseases in rabbits and cattle, although further studies to prove its efficacy in the field on other farm animals are still needed.
format Online
Article
Text
id pubmed-7522943
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Veterinary World
record_format MEDLINE/PubMed
spelling pubmed-75229432020-10-14 Production, immunogenicity, stability, and safety of a vaccine against Clostridium perfringens beta toxins Saadh, Mohamed J. Sa’adeh, Issam J. Dababneh, Moeen F. Almaaytah, Ammar M. Bayan, Mohammad F. Vet World Research Article BACKGROUND AND AIM: The beta toxin is causing the most severe Clostridium perfringens-related diseases. This work was dedicated to developing a vaccine against beta toxin using C. perfringens type C (NCTC 3180). MATERIALS AND METHODS: The crude toxoid harvest contained 710 limits of flocculation (Lf)/mL. The vaccine was formulated. Each 1 mL of the final vaccine product contained at least 50 Lf/mL of beta toxoids, 0.2 mL 3% aluminum hydroxide gel (equivalent to 5.18 mg of aluminum), <0.001% W/V thiomersal, formaldehyde <0.05% W/V, and ~0.7 mL phosphate-buffered saline (pH 7.2). The efficacy of the vaccine was evaluated by potency, stability, and safety tests. RESULTS: The vaccine demonstrated 24.36 IU/mL (standard deviation, ±0.56) and 14.74 IU/mL (±0.36) of neutralizing antibodies in rabbits and cattle, respectively. Indeed, these levels were above the minimum recommended by international protocols since the obtained antibody levels had 2.43- and 1.47-fold increase in both rabbits and cattle, respectively, over the minimum antitoxin level suggested by the United States Department of Agriculture. Interestingly, our formulation was capable of inducing 1.65-fold higher immune responses in rabbits than that stimulated in cattle (65% increase) with a significant difference (p<0.0001). The vaccine was stable up to 30 months. The vaccinated rabbits were suffered from a temporarily slight increase in temperatures in the first 10 h without any significant difference (p>0.05). CONCLUSION: The research showed a procedure for the manufacturing process of the vaccine against C. perfringens beta toxins with a feasible quantity and the vaccine described here showed to be effective in eliciting levels of neutralizing antibodies higher than required by international standards. In addition, The vaccine was stable up to 30 months. Thus, it may represent an effective and safe for preventing C. perfringens-related diseases in rabbits and cattle, although further studies to prove its efficacy in the field on other farm animals are still needed. Veterinary World 2020-08 2020-08-07 /pmc/articles/PMC7522943/ /pubmed/33061221 http://dx.doi.org/10.14202/vetworld.2020.1517-1523 Text en Copyright: © Saadh, et al. http://creativecommons.org/licenses/by/4.0 Open Access. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Saadh, Mohamed J.
Sa’adeh, Issam J.
Dababneh, Moeen F.
Almaaytah, Ammar M.
Bayan, Mohammad F.
Production, immunogenicity, stability, and safety of a vaccine against Clostridium perfringens beta toxins
title Production, immunogenicity, stability, and safety of a vaccine against Clostridium perfringens beta toxins
title_full Production, immunogenicity, stability, and safety of a vaccine against Clostridium perfringens beta toxins
title_fullStr Production, immunogenicity, stability, and safety of a vaccine against Clostridium perfringens beta toxins
title_full_unstemmed Production, immunogenicity, stability, and safety of a vaccine against Clostridium perfringens beta toxins
title_short Production, immunogenicity, stability, and safety of a vaccine against Clostridium perfringens beta toxins
title_sort production, immunogenicity, stability, and safety of a vaccine against clostridium perfringens beta toxins
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7522943/
https://www.ncbi.nlm.nih.gov/pubmed/33061221
http://dx.doi.org/10.14202/vetworld.2020.1517-1523
work_keys_str_mv AT saadhmohamedj productionimmunogenicitystabilityandsafetyofavaccineagainstclostridiumperfringensbetatoxins
AT saadehissamj productionimmunogenicitystabilityandsafetyofavaccineagainstclostridiumperfringensbetatoxins
AT dababnehmoeenf productionimmunogenicitystabilityandsafetyofavaccineagainstclostridiumperfringensbetatoxins
AT almaaytahammarm productionimmunogenicitystabilityandsafetyofavaccineagainstclostridiumperfringensbetatoxins
AT bayanmohammadf productionimmunogenicitystabilityandsafetyofavaccineagainstclostridiumperfringensbetatoxins